The major aim of WP5 is to establish surrogate serum protein profiles for tumour stroma, in order to predict patients’ response to treatment. To this end, surrogate serum cytokine profiles will be established in serum from clinical pancreatic cancer cases recruited in Europe’s largest pancreatic cancer clinical trials (ESPAC and Telovac). An equivalent study will be performed using serum from the mouse models provided in WP3. Relationships between survival, observed stromal level, protein profiles and treatment groups will elucidate the role of stroma in chemotherapy response.
The University of Liverpool, United Kingdom (ULIV) per Participant
Philipps-Universität Marburg, Germany (UNIMAR)
University of Verona, Italy (UNIVR)
Ernst-Moritz-Arndt-Universität Greifswald, Germany (EMAU-G)
Technische Universität München, Klinikum rechts der Isar, Germany (TUM-MED)
Cancer Research UK, United Kingdom (CR-UK)
Lab21 Ltd., United Kingdom (Lab21)